299 related articles for article (PubMed ID: 33813077)
1. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
2. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
[TBL] [Abstract][Full Text] [Related]
5. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as the pivotal regulators of cisplatin resistance in osteosarcoma.
Moghbeli M
Pathol Res Pract; 2023 Sep; 249():154743. PubMed ID: 37549518
[TBL] [Abstract][Full Text] [Related]
7. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
Tsai HC; Huang CY; Su HL; Tang CH
PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
[TBL] [Abstract][Full Text] [Related]
8. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
9. ANXA2 and Rac1 negatively regulates autophagy and osteogenic differentiation in osteosarcoma cells to confer CDDP resistance.
Pan B; Pan Y; Wang S; Bai Y; Hu X; Yang Y; Wu L; Liu J
Biochem Biophys Res Commun; 2023 Oct; 676():198-206. PubMed ID: 37536195
[TBL] [Abstract][Full Text] [Related]
10. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
Huang H; Wang L; Li M; Wang X; Zhang L
World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.
Sun X; Wei Q; Cheng J; Bian Y; Tian C; Hu Y; Li H
Hum Cell; 2017 Jul; 30(3):216-225. PubMed ID: 28326487
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
13. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Huang Z; Huang Y; He H; Ni J
Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
[TBL] [Abstract][Full Text] [Related]
14. GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma.
Xie C; Xiang W; Shen H; Shen J
J Orthop Surg Res; 2021 Dec; 16(1):713. PubMed ID: 34876170
[TBL] [Abstract][Full Text] [Related]
15. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
16. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
[TBL] [Abstract][Full Text] [Related]
17. Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells.
Feng H; Zhang Q; Zhao Y; Zhao L; Shan B
Aging (Albany NY); 2020 Apr; 12(7):6340-6351. PubMed ID: 32289750
[TBL] [Abstract][Full Text] [Related]
18. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
Ferretti VA; León IE
Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
[TBL] [Abstract][Full Text] [Related]
19. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
20. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]